Trial Profile
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Belrestotug (Primary) ; Feladilimab (Primary) ; GSK 6097608 (Primary) ; Docetaxel; Dostarlimab; Ipilimumab
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENTREE
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 13 Sep 2022 Trial design presented at the 47th European Society for Medical Oncology Congress
- 09 Aug 2022 Trial design of part 1 of this study was presented at the 2022 World Conference on Lung Cancer.
- 27 Jun 2022 Planned End Date changed from 3 Jul 2025 to 8 Jul 2025.